198 related articles for article (PubMed ID: 19259670)
41. Targeting primary human leukaemia cells with RNA interference: Bcr-Abl targeting inhibits myeloid progenitor self-renewal in chronic myeloid leukaemia cells.
Withey JM; Marley SB; Kaeda J; Harvey AJ; Crompton MR; Gordon MY
Br J Haematol; 2005 May; 129(3):377-80. PubMed ID: 15842662
[TBL] [Abstract][Full Text] [Related]
42. Naturally processed tissue- and differentiation stage-specific autologous peptides bound by HLA class I and II molecules of chronic myeloid leukemia blasts.
Papadopoulos KP; Suciu-Foca N; Hesdorffer CS; Tugulea S; Maffei A; Harris PE
Blood; 1997 Dec; 90(12):4938-46. PubMed ID: 9389712
[TBL] [Abstract][Full Text] [Related]
43. The molecular pathology of chronic myelogenous leukaemia.
Kurzrock R; Talpaz M
Br J Haematol; 1991 Oct; 79 Suppl 1():34-7. PubMed ID: 1931706
[TBL] [Abstract][Full Text] [Related]
44. BCR-ABL is not an immunodominant antigen in chronic myelogenous leukemia.
Grünebach F; Mirakaj V; Mirakaj V; Müller MR; Brümmendorf T; Brossart P
Cancer Res; 2006 Jun; 66(11):5892-900. PubMed ID: 16740729
[TBL] [Abstract][Full Text] [Related]
45. Potential role of Notch signalling in CD34+ chronic myeloid leukaemia cells: cross-talk between Notch and BCR-ABL.
Aljedai A; Buckle AM; Hiwarkar P; Syed F
PLoS One; 2015; 10(4):e0123016. PubMed ID: 25849484
[TBL] [Abstract][Full Text] [Related]
46. Modulation of cell kinetics and cell cycle status by treating CD34+ chronic myeloid leukaemia cells with p53 antisense phosphorothioate oligonucleotides.
Lanza F; Bi S; Moretti S; Castoldi G; Goldman JM
Br J Haematol; 1995 May; 90(1):8-14. PubMed ID: 7786800
[TBL] [Abstract][Full Text] [Related]
47. Chronic myelogenous leukemia: molecular and cellular aspects.
Pasternak G; Hochhaus A; Schultheis B; Hehlmann R
J Cancer Res Clin Oncol; 1998; 124(12):643-60. PubMed ID: 9879825
[TBL] [Abstract][Full Text] [Related]
48. Vaccination with autologous non-irradiated dendritic cells in patients with bcr/abl+ chronic myeloid leukaemia.
Westermann J; Kopp J; van Lessen A; Hecker AC; Baskaynak G; le Coutre P; Döhner K; Döhner H; Dörken B; Pezzutto A
Br J Haematol; 2007 May; 137(4):297-306. PubMed ID: 17408402
[TBL] [Abstract][Full Text] [Related]
49. Inhibition of proteasomal deubiquitinases USP14 and UCHL5 overcomes tyrosine kinase inhibitor resistance in chronic myeloid leukaemia.
Jiang L; He Q; Chen X; Liu A; Ding W; Zhang H; Chen X; Zhou H; Meng Y; Liu B; Peng G; Wang C; Liu J; Shi X
Clin Transl Med; 2022 Sep; 12(9):e1038. PubMed ID: 36082692
[TBL] [Abstract][Full Text] [Related]
50. HLA-DRB1*16-restricted recognition of myeloid cells, including CD34+ CML progenitor cells.
Ebeling SB; Ivanov R; Hol S; Aarts TI; Hagenbeek A; Verdonck LF; Petersen EJ
Br J Haematol; 2003 Jun; 121(5):721-9. PubMed ID: 12780786
[TBL] [Abstract][Full Text] [Related]
51. BCR-ABL fusion regions as a source of multiple leukemia-specific CD8+ T-cell epitopes.
Kessler JH; Bres-Vloemans SA; van Veelen PA; de Ru A; Huijbers IJ; Camps M; Mulder A; Offringa R; Drijfhout JW; Leeksma OC; Ossendorp F; Melief CJ
Leukemia; 2006 Oct; 20(10):1738-50. PubMed ID: 16932347
[TBL] [Abstract][Full Text] [Related]
52. Immunological characterization of the tumor-specific bcr/abl junction of Philadelphia chromosome positive chronic myeloid leukemia.
Barrett J; Guimaraes A; Cullis J; Goldman JM
Stem Cells; 1993 Oct; 11 Suppl 3():104-8. PubMed ID: 8298471
[TBL] [Abstract][Full Text] [Related]
53. Cytokine enhancement of immunogenicity in chronic myeloid leukaemia.
Coleman S; Throp D; Fisher J; Bailey-Wood R; Lim SH
Leukemia; 1997 Dec; 11(12):2055-9. PubMed ID: 9447820
[TBL] [Abstract][Full Text] [Related]
54. Comparison of
DE Oliveira Sales L; Mesquita FP; DE Sousa Portilho AJ; DE Moraes Filho MO; DE Moraes MEA; Montenegro RC; Moreira-Nunes CA
In Vivo; 2019; 33(4):1119-1124. PubMed ID: 31280200
[TBL] [Abstract][Full Text] [Related]
55. Immunogenicity of a p210(BCR-ABL) fusion domain candidate DNA vaccine targeted to dendritic cells by a recombinant adeno-associated virus vector in vitro.
Sun JY; Krouse RS; Forman SJ; Senitzer D; Sniecinski I; Chatterjee S; Wong KK
Cancer Res; 2002 Jun; 62(11):3175-83. PubMed ID: 12036931
[TBL] [Abstract][Full Text] [Related]
56. P190BCR-ABL chronic myeloid leukaemia: the missing link with chronic myelomonocytic leukaemia?
Melo JV; Myint H; Galton DA; Goldman JM
Leukemia; 1994 Jan; 8(1):208-11. PubMed ID: 8289491
[TBL] [Abstract][Full Text] [Related]
57. BCR/ABL leukemia oncogene fusion peptides selectively bind to certain HLA-DR alleles and can be recognized by T cells found at low frequency in the repertoire of normal donors.
Pawelec G; Max H; Halder T; Bruserud O; Merl A; da Silva P; Kalbacher H
Blood; 1996 Sep; 88(6):2118-24. PubMed ID: 8822931
[TBL] [Abstract][Full Text] [Related]
58. Graft-versus-leukemia effects of Wilms' tumor 1 protein-specific cytotoxic T lymphocytes in patients with chronic myeloid leukemia after allogeneic hematopoietic stem cell transplantation.
Wang ZD; Li D; Huang XJ
Chin Med J (Engl); 2010 Apr; 123(7):912-6. PubMed ID: 20497687
[TBL] [Abstract][Full Text] [Related]
59. Application of the pMHC Array to Characterise Tumour Antigen Specific T Cell Populations in Leukaemia Patients at Disease Diagnosis.
Brooks SE; Bonney SA; Lee C; Publicover A; Khan G; Smits EL; Sigurdardottir D; Arno M; Li D; Mills KI; Pulford K; Banham AH; van Tendeloo V; Mufti GJ; Rammensee HG; Elliott TJ; Orchard KH; Guinn BA
PLoS One; 2015; 10(10):e0140483. PubMed ID: 26492414
[TBL] [Abstract][Full Text] [Related]
60. Antibody recognition of the tumor-specific bcr-abl joining region in chronic myeloid leukemia.
van Denderen J; Hermans A; Meeuwsen T; Troelstra C; Zegers N; Boersma W; Grosveld G; van Ewijk W
J Exp Med; 1989 Jan; 169(1):87-98. PubMed ID: 2462613
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
